Recovery of Sensorimotor Gating without G Protein Adaptation after Repeated D2-Like Dopamine Receptor Agonist Treatment in Rats

Kerry E. Culm, Ronald P Hammer

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Sensorimotor gating, a neural process severely disrupted in patients with schizophrenia, can be measured by assessing prepulse inhibition (PPI) of acoustic startle responses. PPI is disrupted in experimental animals by stimulation of D2-like dopamine receptors in the nucleus accumbens (NAc). We examined the effect of repeated treatment with a selective dopamine D2-like receptor agonist, quinpirole, and characterized the molecular substrates of the resulting PPI adaptation. Animals were treated once daily for 10 or 28 consecutive days with quinpirole (0.0, 0.05, 0.1, or 0.3 mg/kg, s.c.), and the effect on PPI was assessed throughout the treatment period. PPI was reduced after acute quinpirole administration, but gradually increased with repeated treatment. Quinpirole-induced PPI disruption was attenuated after 10 days of treatment at lower doses, but complete recovery was not apparent until the treatment period was extended to 28 days. Since chronic drug exposure can alter the dopamine system, we sought to characterize the effects of repeated quinpirole treatment on G proteins coupled to D 2-like receptors in the NAc. Guanosine 5′-O-(3-[ 35S]thiotriphosphate) ([35S]GTPγS) binding and Western blot analysis revealed that repeated quinpirole treatment had no effect on NAc D2-like receptor G protein function or G protein levels. These data indicate that repeated activation of D2-like receptors by quinpirole produces tolerance in the absence of receptor or G protein changes, suggesting that the locus of dopaminergic adaptation might be at the intracellular level.

Original languageEnglish (US)
Pages (from-to)487-494
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume308
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Sensory Gating
Quinpirole
Dopamine Agonists
GTP-Binding Proteins
Nucleus Accumbens
Dopamine D2 Receptors
Therapeutics
Startle Reflex
Guanosine 5'-O-(3-Thiotriphosphate)
Acoustics
Prepulse Inhibition
Dopamine
Schizophrenia
Western Blotting

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{a293f495669d4c8396e82e24ea36034e,
title = "Recovery of Sensorimotor Gating without G Protein Adaptation after Repeated D2-Like Dopamine Receptor Agonist Treatment in Rats",
abstract = "Sensorimotor gating, a neural process severely disrupted in patients with schizophrenia, can be measured by assessing prepulse inhibition (PPI) of acoustic startle responses. PPI is disrupted in experimental animals by stimulation of D2-like dopamine receptors in the nucleus accumbens (NAc). We examined the effect of repeated treatment with a selective dopamine D2-like receptor agonist, quinpirole, and characterized the molecular substrates of the resulting PPI adaptation. Animals were treated once daily for 10 or 28 consecutive days with quinpirole (0.0, 0.05, 0.1, or 0.3 mg/kg, s.c.), and the effect on PPI was assessed throughout the treatment period. PPI was reduced after acute quinpirole administration, but gradually increased with repeated treatment. Quinpirole-induced PPI disruption was attenuated after 10 days of treatment at lower doses, but complete recovery was not apparent until the treatment period was extended to 28 days. Since chronic drug exposure can alter the dopamine system, we sought to characterize the effects of repeated quinpirole treatment on G proteins coupled to D 2-like receptors in the NAc. Guanosine 5′-O-(3-[ 35S]thiotriphosphate) ([35S]GTPγS) binding and Western blot analysis revealed that repeated quinpirole treatment had no effect on NAc D2-like receptor G protein function or G protein levels. These data indicate that repeated activation of D2-like receptors by quinpirole produces tolerance in the absence of receptor or G protein changes, suggesting that the locus of dopaminergic adaptation might be at the intracellular level.",
author = "Culm, {Kerry E.} and Hammer, {Ronald P}",
year = "2004",
month = "2",
doi = "10.1124/jpet.103.057158",
language = "English (US)",
volume = "308",
pages = "487--494",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Recovery of Sensorimotor Gating without G Protein Adaptation after Repeated D2-Like Dopamine Receptor Agonist Treatment in Rats

AU - Culm, Kerry E.

AU - Hammer, Ronald P

PY - 2004/2

Y1 - 2004/2

N2 - Sensorimotor gating, a neural process severely disrupted in patients with schizophrenia, can be measured by assessing prepulse inhibition (PPI) of acoustic startle responses. PPI is disrupted in experimental animals by stimulation of D2-like dopamine receptors in the nucleus accumbens (NAc). We examined the effect of repeated treatment with a selective dopamine D2-like receptor agonist, quinpirole, and characterized the molecular substrates of the resulting PPI adaptation. Animals were treated once daily for 10 or 28 consecutive days with quinpirole (0.0, 0.05, 0.1, or 0.3 mg/kg, s.c.), and the effect on PPI was assessed throughout the treatment period. PPI was reduced after acute quinpirole administration, but gradually increased with repeated treatment. Quinpirole-induced PPI disruption was attenuated after 10 days of treatment at lower doses, but complete recovery was not apparent until the treatment period was extended to 28 days. Since chronic drug exposure can alter the dopamine system, we sought to characterize the effects of repeated quinpirole treatment on G proteins coupled to D 2-like receptors in the NAc. Guanosine 5′-O-(3-[ 35S]thiotriphosphate) ([35S]GTPγS) binding and Western blot analysis revealed that repeated quinpirole treatment had no effect on NAc D2-like receptor G protein function or G protein levels. These data indicate that repeated activation of D2-like receptors by quinpirole produces tolerance in the absence of receptor or G protein changes, suggesting that the locus of dopaminergic adaptation might be at the intracellular level.

AB - Sensorimotor gating, a neural process severely disrupted in patients with schizophrenia, can be measured by assessing prepulse inhibition (PPI) of acoustic startle responses. PPI is disrupted in experimental animals by stimulation of D2-like dopamine receptors in the nucleus accumbens (NAc). We examined the effect of repeated treatment with a selective dopamine D2-like receptor agonist, quinpirole, and characterized the molecular substrates of the resulting PPI adaptation. Animals were treated once daily for 10 or 28 consecutive days with quinpirole (0.0, 0.05, 0.1, or 0.3 mg/kg, s.c.), and the effect on PPI was assessed throughout the treatment period. PPI was reduced after acute quinpirole administration, but gradually increased with repeated treatment. Quinpirole-induced PPI disruption was attenuated after 10 days of treatment at lower doses, but complete recovery was not apparent until the treatment period was extended to 28 days. Since chronic drug exposure can alter the dopamine system, we sought to characterize the effects of repeated quinpirole treatment on G proteins coupled to D 2-like receptors in the NAc. Guanosine 5′-O-(3-[ 35S]thiotriphosphate) ([35S]GTPγS) binding and Western blot analysis revealed that repeated quinpirole treatment had no effect on NAc D2-like receptor G protein function or G protein levels. These data indicate that repeated activation of D2-like receptors by quinpirole produces tolerance in the absence of receptor or G protein changes, suggesting that the locus of dopaminergic adaptation might be at the intracellular level.

UR - http://www.scopus.com/inward/record.url?scp=1642457233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642457233&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.057158

DO - 10.1124/jpet.103.057158

M3 - Article

VL - 308

SP - 487

EP - 494

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -